CompletedPhase IInterventional

Phase I Study: Quotient Code QSC300759

This is an early-stage research study, known as a Phase I trial, investigating a new medicine called QSC300759. The main goal of such trials is to test if a new medicine is safe and how it behaves in the body, rather than whether it can treat a specific illness. This particular study is open to both men and women between the ages of 18 and 55. At this moment, the organisations running the study have decided not to release all the detailed information about the trial, including what conditions it might be for or what exactly will happen to participants. However, they have promised to make all the full details public within 30 months after the study has finished.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Novartis Pharmaceuticals UK Limited

Enrolment target

Start

05 Nov 2025

Estimated completion

22 Feb 2026

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study is an early step in developing a new medicine, given the code QSC300759. It's called a "Phase I" study, which means the researchers are mainly focused on making sure the medicine is safe when given to people and understanding how it works inside the body, such as how much of it the body uses and how it gets rid of it. This stage isn't usually about whether the medicine can cure a disease, but rather about gathering fundamental information.

At the moment, the researchers have decided not to share all the specific details about this study and the new medicine. This can happen for various reasons, for example, to protect new scientific discoveries until they are more developed. While this means we don't have all the information right now, it's a standard practice in some research.

The good news is that all the important information will be made public eventually. The organisations running the study have committed to releasing the full details within 30 months after the study comes to an end. This includes what the medicine is being developed for and the specific steps involved in the trial.

Key takeaways

This is an early-stage (Phase I) study of a new medicine, QSC300759.
The study aims to check the new medicine's safety and how it works in the body.
It's open to adults aged 18 to 55, both men and women.
Full details about the study, including eligibility and procedures, are not yet publicly available.
All study details will be released within 30 months after the trial has ended.

Who may be eligible?

This study is open to adults who are between 18 and 55 years old, inclusive. Both men and women are welcome to take part.

Right now, the full list of other health conditions or situations that might prevent someone from joining isn't available. This detailed information will be published later.

Typically, in these early-stage studies, participants are generally healthy volunteers, but we don't have confirmation of that for this specific trial at this time.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I at least 18 years old?
Am I no older than 55 years old?
Am I either male or female? (Both are eligible)
Am I generally healthy?

Answer every question to see your result.

What does participation involve?

Because the full details of this study are not yet public, we don't have specific information about what taking part would involve. Generally, in a Phase I study like this, you might expect to:

* **Have multiple visits:** This could include screening appointments to check if you're suitable, visits to receive the medicine, and follow-up check-ups. * **Undergo various assessments:** These often include blood tests, urine tests, physical examinations, and possibly heart scans or other checks to monitor your health and how the medicine is affecting you. * **Receive the study medicine:** You would be given the new medicine, likely at different doses, and your reactions would be closely monitored. * **Have follow-up:** After you've received the medicine, there would be follow-up appointments to ensure your well-being and to collect all the necessary data. * **Total duration:** The overall time commitment for participants in Phase I studies can vary greatly, from a few days to several weeks or even months, depending on how the medicine is given and how long its effects need to be monitored. Specific details for this study will be published later.

Potential risks and benefits

Since the full details of this study are not yet available, we can't list specific potential benefits or risks. However, in any research study, there's always a chance of unknown side effects from a new medicine. There may not be direct health benefits to you personally, as early studies focus on safety. Your health will be carefully monitored throughout. Remember, taking part in any study is completely voluntary, and you have the right to withdraw at any time for any reason without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, United Kingdom

Common questions

What is a Phase I study?

A Phase I study is the first step where a new medicine is tested in people. The main goals are to check if it's safe and how it behaves in the body, rather than if it can treat a specific illness.

What is QSC300759?

QSC300759 is a code name for a new medicine being tested. We don't have much detail about what it's for yet, but it's part of early research.

How old do I need to be to join?

You need to be between 18 and 55 years old to be considered for this study.

Can women take part?

Yes, both men and women are eligible to participate in this study.

When will more details about the study be available?

The full details about the study will be made public within 30 months after the study has finished.

How to find out more

Novartis Study Director

novartis.email@novartis.com +41 (0)61 324 11 11 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.